Santen Pharmaceutical Co., Ltd. (TYO:4536)

Santen Pharmaceutical Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	37,561	35,853	26,703	-14,983	27,189
Depreciation & Amortization	18,358	17,948	18,178	17,249	17,055
Loss (Gain) From Sale of Assets	3,841	1,302	7,779	34,560	232
Loss (Gain) on Equity Investments	-	685	7,575	2,362	1,604
Other Operating Activities	-7,642	-12,288	-12,287	-7,990	-10,318
Change in Accounts Receivable	2,669	18,512	18,384	-6,443	-1,965
Change in Inventory	-10,025	-8,381	-1,369	-1,144	5,383
Change in Accounts Payable	-4,024	-9,586	-2,369	1,690	2,748
Change in Other Net Operating Assets	2,762	16,883	10,055	11,846	4,115
Operating Cash Flow	43,500	60,928	72,649	37,147	46,043
Operating Cash Flow Growth	-28.60%	-16.13%	95.57%	-19.32%	18.64%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-6,844	-6,662	-9,319	-17,277	-17,344
Cash Acquisitions	-	-	-207	-3,470	-2,969
Sale (Purchase) of Intangibles	-6,469	-4,357	-572	-7,311	-18,497
Investment in Securities	360	3,152	3,826	1,560	2,803
Other Investing Activities	-21	-356	127	-279	838
Investing Cash Flow	-12,974	-8,223	-6,145	-26,777	-35,169

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	-	-	-	-	10,460
Long-Term Debt Issued	-	-	-	15,639	10,000
Total Debt Issued	-	-	-	15,639	20,460
Short-Term Debt Repaid	-	-	-	-11,278	-
Long-Term Debt Repaid	-	-158	-2,112	-	-
Total Debt Repaid	-	-158	-2,112	-11,278	-
Net Debt Issued (Repaid)	-	-158	-2,112	4,361	20,460
Repurchase of Common Stock	-32,797	-37,883	-16,962	-26,007	-
Common Dividends Paid	-12,642	-12,111	-11,881	-12,607	-11,994
Other Financing Activities	-3,909	-3,155	-3,076	-2,967	-2,909
Financing Cash Flow	-49,348	-53,307	-34,031	-37,220	5,557

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	6,700	-983	4,206	1,739	3,694
Miscellaneous Cash Flow Adjustments	-	-	-	-	1
Net Cash Flow	-12,122	-1,585	36,679	-25,111	20,126

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	36,656	54,266	63,330	19,870	28,699
Free Cash Flow Growth	-32.45%	-14.31%	218.72%	-30.76%	-17.22%
Free Cash Flow Margin	12.57%	18.09%	20.97%	7.12%	10.78%
Free Cash Flow Per Share	111.63	155.18	172.03	51.29	71.67
Levered Free Cash Flow	17,273	40,191	57,849	10,007	6,630
Unlevered Free Cash Flow	18,142	40,867	58,369	10,305	6,786

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	1,263	1,093	830	465	240
Cash Income Tax Paid	7,437	12,188	12,108	7,818	10,246
Change in Working Capital	-8,618	17,428	24,701	5,949	10,281

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 29, 2026

Data Sources Report a data error